The NICE Board is anticipated to endorse changes to the way medicines and other health technology are reviewed for use in the NHS.
If accepted, the revisions will provide patients faster access to medicines and therapies, increase predictability for industry, encourage honesty with stakeholders, and allow NICE's independent committees to make decisions more quickly.
“The changes being discussed will provide a robust foundation for our evaluations now and in the future“
CEO at NICE, Professor Gillian Leng, expressed that “The changes being discussed will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments.”
“Going forward, NICE will adopt a more modular approach to updates to its methods and processes. This will enable us to be more agile and responsive, monitoring, reviewing, and improving our methods and processes into the future, making sure they remain cutting edge as the healthcare landscape continues to evolve.”
One of the programme directors at NICE, Helen Knight, explained that they have “engaged extensively with our stakeholders throughout this process, and we’ve listened to their concerns and taken on board many of their suggestions.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.See all the latest jobs in Medical Devices